Biotech Values

[walldiver]

SNUS-The PFS results won't be available until at least Q2/Q3 2008. The primary endpoint is ORR. I'm guessing that TOCp hit stat sig on noninferiority, with a trend toward superiority, and showed an improved side effect profile. From all of the Ph2 results, this scenario had the highest odds. We'll see.

Edit: the p value for both superiority and noninferiority is 0.025.